1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Myocardial Infarction Drugs Market 2016-2020

Global Myocardial Infarction Drugs Market 2016-2020

  • March 2016
  • -
  • Infiniti Research Limited
  • -
  • 75 pages

About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Technavio’s analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
- Pfizer
- Sanofi


Other prominent vendors
- advanceCOR
- Armaron Bio
- Athersys
- BioVascular
- BMS
- Caladrius
- Capricor
- CSL Behring
- GNT Pharma
- GSK
- Ischemix
- Mesoblast
- NeuroVive
- Osiris Therapeutics
- PledPharma
- RegeneRx
- Teva Pharmaceuticals
- TiGenix
- US Stem Cell
- Ventrix

Market driver
- Growing older population
- For a full, detailed list, view our report

Market challenge
- Alternative therapies
- For a full, detailed list, view our report

Market trend
- Growing awareness of disease
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Myocardial Infarction Drugs Market 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
- Key buying criteria
PART 05: Disease overview
- Types of myocardial infarction
- Pathophysiology
- Risk factors
- Diagnosis
- Management
PART 06: Epidemiology and economic burden
- Burden of disease
PART 07: Pipeline analysis
- Canakinumab
- MyoCell
- MultiStem therapy
- CLBS10
- Prochymal
- Revascor
- CicloMulsion
- PP-099
- NP202
- CAP-1002
- Revacept
- CSL112
PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 09: Market segmentation by drug class
- Beta blockers
- ACE inhibitors
- ARBs
- Vasodilators
- Antithrombotic agents
- Thrombolytics
- Glycoprotein IIb/IIIa inhibitors
- Anti-dyslipidemic drugs
- Calcium channel blockers
- Analgesics
PART 10: Market segmentation by EKG appearance
- NSTEMI
- STEMI
PART 11: Market segmentation by type
- Brand-name drugs
- Generic drugs
PART 12: Geographical segmentation
- Global myocardial infarction drugs market segmentation by geography 2015-2020
- Myocardial infarction drugs market in Americas
- Myocardial infarction drugs market in EMEA
- Myocardial infarction drugs market in APAC
PART 13: Market drivers
- Increase in older population
- Sedentary lifestyle
- Rise in obesity
- High prevalence of chronic conditions
PART 14: Impact of drivers
PART 15: Market challenges
- Delayed diagnosis
- Alternative therapies
- Extensive use of generics
PART 16: Impact of drivers and challenges
PART 17: Market trends
- Growing awareness of disease
- Strategic alliances
- Increased RandD
- Prevalent use of stent grafts
PART 18: Vendor landscape
- Competitive scenario
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
- Pfizer
- Sanofi
- Other prominent vendors
PART 19: Appendix
- List of abbreviations
PART 20: Explore Technavio



List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for myocardial infarction drugs
Exhibit 03: Pathophysiology of myocardial infarction
Exhibit 04: Risk factors of myocardial infarction
Exhibit 05: Diagnostic techniques for myocardial infarction
Exhibit 06: Treatment options for myocardial infarction
Exhibit 07: Projected prevalence of CVDs in US
Exhibit 08: Projected economic burden for CVDs in US
Exhibit 09: Pipeline portfolio: Myocardial infarction
Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
Exhibit 28: AstraZeneca: Key takeaways
Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
Exhibit 31: Bayer HealthCare: Key takeaways
Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
Exhibit 35: Eli Lilly: Key takeaways
Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
Exhibit 38: Novartis: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
Exhibit 46: Sanofi: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Myocardial Infarction  - Market Insights, Epidemiology and Market Forecast-2023

Myocardial Infarction  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Myocardial Infarction - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Myocardial Infarction fo ...

Myocardial Infarction  - Epidemiology Forecast To 2023

Myocardial Infarction  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Myocardial Infarction  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Myocardial Infarction  in seven major markets (US, France, Germany, Italy, ...

Myocardial Infarction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Myocardial Infarction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Myocardial Infarction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.